Reducing morbidity and mortality in high risk patients with statins

Figures & data

Figure 1 Kaplan-Meier estimates of the incidence of major cardiovascular events in patients with diabetes mellitus (includes congestive heart failure death, non-fatal nonprocedure-related acute myocardial infarction, resuscitated cardiac arrest, and fatal or non-fatal stroke).

Abbreviations: HR, hazard ratio; CI, confidence interval.

Table 1 Goals and end points for lipid-lowering therapy (modified from NCEP ATP III recommendations)

Risk level	High risk	Intermediate risk	Low risk
Number of risk factors	CHD, CHD risk equivalents	≥2 risk factors	0–1 risk factors
10-year risk	>20%	10%–20%	<10%
Target LDL-cholesterol level (mg/dL)	<100 <70 (very high risk)	>130	>160
End point for initiating drug therapy	<130	>160	>190

Abbreviations: CHD, congestive heart failure; LDL-cholesterol, low-density lipoprotein cholesterol.

Table 2 Cardiovascular events in patients with metabolic syndrome at various doses of atorvastatin

	Low dose atorvastatin	High dose atorvastatin
n	2820	2764
Major cardiovascular events (%)	13.0%	9.5%
Hazard ratio	–	0.71
95% confidence interval	–	0.61–0.84
p	–	<0.0001

Table 3 Percentage of patients with decline or improvement from baseline eGFR

	Low dose atorvastatin	High dose atorvastatin	p
Decline in eGFR	9.2%	6.6%	<0.0001
Improvement in eGFR	37.8%	45.6%	<0.0001

Notes: Decline signifies a baseline estimated glomerular filtration rate (eGFR) 60 mL/min/1.73 m² and a last visit eGFR <60 mL/min/1.73 m²; improvement signifies a baseline eGFR <60 and a last visit eGFR 60 mL/min/1.73 m².